PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107
- Registration Number
- NCT00137423
- Locations
- ๐จ๐ญ
Pfizer Investigational Site, St. Gallen, Switzerland
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00137449
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Milano, Italy
Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00136968
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 93
- Registration Number
- NCT00137436
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Madison, Wisconsin, United States
Zithromax EV in Community-Acquired Pneumonia (CAP)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT00137007
Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2008-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00137410
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Venezia, Italy
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2010-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 582
- Registration Number
- NCT00137046
- Locations
- ๐ฒ๐ฝ
Pfizer Investigational Site, Monterrey, Nuevo Leon, Mexico
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2007-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 900
- Registration Number
- NCT00137462
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, St. Georges de Beauce, Quebec, Canada
Irinotecan Study For Cervical Cancer
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00136955
- Locations
- ๐จ๐ณ
Pfizer Investigational Site, Taipei, Taiwan
Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 800
- Registration Number
- NCT00136981
- Locations
- ๐ฟ๐ฆ
Pfizer Investigational Site, Cape Town, South Africa
ยฉ Copyright 2024. All Rights Reserved by MedPath